Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Diffuse Large B Cell Lymphoma
Clinical trial register · United States · industry-sponsored

Diffuse Large B Cell Lymphoma Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9159 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Oct 2026, 03:16 UTC
9159
Studies in scope
industry-sponsored, all four open statuses
4969
Recruiting now
open to new participants
2198
Lead sponsors
across recruiting studies
Top states
California 18 Florida 17 Texas 11 Maryland 8 Massachusetts 8
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Diffuse Large B Cell Lymphoma trials in the USA

28 of 9159 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
NCT07750886Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma
Natera, Inc.
Observational
200
Texas
2026-07-27
Active, closed
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
NCT06323447Diffuse Large B Cell Lymphoma, Multiple Myeloma
Leuko Labs, Inc.
Observational
210
Hawaii, Kentucky, Massachusetts, New Jersey, Texas
2025-12-15
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2024-08-16
Recruiting
AstraZeneca
Phase 2
80
California, Connecticut, Florida, Iowa, Kentucky, Maryland, Michigan, South Dakota
2024-07-16
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
OncoNano Medicine, Inc.
Phase 1
168
California, Florida, Ohio, Pennsylvania, Texas, Virginia
2023-10-13
Recruiting
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
NCT05365659B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
Iksuda Therapeutics Ltd.
Phase 1
140
Maryland
2023-09-05
Active, closed
AbbVie
Phase 1
39
Arizona, Florida, Minnesota, Nebraska, New York, North Carolina, Texas
2023-04-26
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
California, Connecticut, Florida, Indiana, Louisiana, Michigan, New York, North Carolina
2023-04-04
Active, closed
Genmab
Phase 2
184
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2022-08-17
Active, closed
Incyte Corporation
Phase 1/2
53
New Jersey, Texas, Washington
2022-07-19
Recruiting
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
NCT05255354Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
Adaptive Biotechnologies
Observational
300
California
2022-06-01
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Arizona, California, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2022-01-14
Active, closed
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
NCT04526834Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
Tessa Therapeutics
Phase 1
21
California, Tennessee, Texas
2021-09-08
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745CLL/SLL, Waldenstrom Macroglobulinemia, Follicular Lymphoma, Diffuse Large B Cell Lymphoma
Newave Pharmaceutical Inc
Phase 1
60
North Carolina, Ohio, Utah
2021-07-19
Active, closed
Incyte Corporation
Phase 3
899
Alabama, California, Colorado, Florida, Hawaii, Kansas, Kentucky, Maryland
2021-05-11
Active, closed
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
NCT04594642B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
AstraZeneca
Phase 1
226
Florida, Kentucky, New Jersey, North Carolina, Ohio, Pennsylvania, Texas, Wisconsin
2021-03-02
Active, closed
Hoffmann-La Roche
Phase 3
270
Alabama, California, Florida, Maryland, Massachusetts, Mississippi, New Jersey, New York
2021-02-23
Recruiting
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Kartos Therapeutics, Inc.
Phase 1/2
84
Indiana, Ohio, Texas
2021-02-23
Active, closed
Genmab
Phase 3
483
Indiana, Kentucky, Michigan, Minnesota, New Jersey, North Carolina, Ohio, Texas
2021-01-13
Active, closed
Genmab
Phase 1/2
543
Alabama, California, Massachusetts, Michigan, New Jersey, New York, North Carolina, Texas
2020-11-03
Active, closed
Acerta Pharma BV
Phase 3
611
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Iowa
2020-10-08
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
240
Alabama, California, Florida, Kansas, Maryland, Michigan, Missouri, Ohio
2020-08-20
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
Novartis Pharmaceuticals
Phase 1/2
300
Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan, New Jersey, New York
2019-09-18
Active, closed
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
Phase 1/2
217
California, Florida, Illinois, Kansas, Massachusetts, Pennsylvania, Tennessee, Texas
2019-06-26
Active, closed
Karyopharm Therapeutics Inc
Phase 2
244
Arizona, California, Florida, Illinois, Kentucky, Massachusetts, New Jersey, New York
2014-11
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/diffuse-large-b-cell-lymphoma

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,159 studies in total at the last sync on 25 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies listing the condition Diffuse Large B Cell Lymphoma.

How many Diffuse Large B Cell Lymphoma trials are recruiting in the US?

11 of the 28 studies on this page are recruiting new participants as of the 25 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diffuse Large B Cell Lymphoma), 28 studies
PhaseStudiesRecruitingShare
Phase 38128.6%
Phase 17325%
Phase 1/26321.4%
Observational3210.7%
Phase 23110.7%
Phase 2/3113.6%

Most active sponsors

Lead sponsors with the most studies (Diffuse Large B Cell Lymphoma)
Lead sponsorStudiesRecruiting
Genmab50
Merck Sharp & Dohme LLC33
AbbVie20
AstraZeneca21
Incyte Corporation20
Novartis Pharmaceuticals21
Acerta Pharma BV10
Adaptive Biotechnologies11
Hoffmann-La Roche10
Iksuda Therapeutics Ltd.11

Top states

Top states (Diffuse Large B Cell Lymphoma), by number of studies with a site there
StateStudies
California18
Florida17
Texas11
Kentucky8
Maryland8
Massachusetts8
Michigan8
New Jersey8
Colorado7
Illinois7
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.